Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Goodwill (2023 - 2026)

bioAffinity Technologies has reported Goodwill over the past 4 years, most recently at $1.4 million for Q1 2026.

  • Quarterly Goodwill changed 0.0% to $1.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Mar 2026, changed 0.0% year-over-year, with the annual reading at $1.4 million for FY2025, 0.0% changed from the prior year.
  • Goodwill was $1.4 million for Q1 2026 at bioAffinity Technologies, roughly flat from $1.4 million in the prior quarter.
  • Over five years, Goodwill peaked at $1.4 million in Q4 2023 and troughed at $1.1 million in Q3 2023.
  • The 4-year median for Goodwill is $1.4 million (2023), against an average of $1.4 million.
  • The largest YoY upside for Goodwill was 22.28% in 2024 against a maximum downside of 0.0% in 2024.
  • A 4-year view of Goodwill shows it stood at $1.4 million in 2023, then changed by 0.0% to $1.4 million in 2024, then changed by 0.0% to $1.4 million in 2025, then changed by 0.0% to $1.4 million in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Goodwill are $1.4 million (Q1 2026), $1.4 million (Q4 2025), and $1.4 million (Q3 2025).